Middle Eastern rhinoplasty requires especially precise preoperative planning to achieve a successful result. Among all aesthetic surgery procedures, there is a higher demand for rhinoplasty among Middle Eastern cultures. The key is to maintain the ethnicity of the patients while meeting their goals. In this brief overview, common features in Middle Eastern patients and Middle Eastern rhinoplasty techniques in men and women are highlighted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326597 | PMC |
| http://dx.doi.org/10.1097/GOX.0000000000001984 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Value of using the ICF Core Set for patients with Musculoskeletal Conditions in Outpatient Rehabilitation Facilities in South-Eastern Poland.
Ann Agric Environ Med
December 2024
Institute of Medical Sciences, College of Medical Sciences of the University of Rzeszów, Poland.
Introduction And Objective: A biopsychosocial model for assessing the functioning of patients with musculoskeletal diseases is essential for planning health services for this patient group. For this purpose, the International Classification of Functioning, Disability and Health (ICF) and the 'core sets' created on its basis are used. The aim of this study was to validate and evaluate the effectiveness of the application of the ICF classification in the assessment of patients with musculoskeletal problems in outpatient rehabilitation facilities.
View Article and Find Full Text PDFCoronary angiography, an invasive diagnostic procedure, often induces pain and anxiety in patients. Despite the potential for alleviating discomfort, the use of stress balls as a nonpharmacological intervention during angiography remains underexplored. This study is aimed at investigating the impact of stress ball application on pain and anxiety levels in patients undergoing angiography.
View Article and Find Full Text PDFCOVID-19 infection and later risk of sickness absence by socioeconomic status: a cohort study.
BMC Public Health
December 2024
Finnish Institute of Occupational Health, TYÖTERVEYSLAITOS, PL 18, Helsinki, 00032, Finland.
Background: The COVID-19 pandemic was a significant health risk and resulted in increased sickness absence during the pandemic. This study examines whether a history of COVID-19 infection is associated with a higher risk of subsequent sickness absence.
Methods: In this prospective cohort study, 32,124 public sector employees responded to a survey on COVID-19 infection and lifestyle factors in 2020 and were linked to sickness absence records before (2019) and after (2021-2022) the survey.
Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience.
BMC Urol
December 2024
Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Background: Immune checkpoint inhibitors (ICIs) alone or in combination with standard chemotherapy for advanced urothelial carcinoma (UC) have been tested as first-line treatment in clinical trials. This study aimed to evaluate the clinical outcomes of programmed cell death 1 (PD-1) inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic UC in a real world clinical care setting, and sought to identify prognostic factors for overall survival (OS).
Methods: A retrospective, real-world study involving 35 locally advanced or metastatic UC patients treated with PD-1 inhibitor alone or in combination with chemotherapy was conducted.
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Anticancer Res
January 2025
Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
Article Synopsis
- A study explored salvage chemotherapy using capecitabine plus oxaliplatin (XELOX) for gastric cancer patients who couldn't tolerate or were resistant to cisplatin, but it was halted due to low patient enrollment.
- 12 patients participated, revealing a disease control rate of 90% and a response rate of 30%, with median progression-free survival of 4.2 months and overall survival of 7.1 months.
- Common severe side effects included fatigue and low potassium levels, but there were no treatment-related deaths, suggesting XELOX might be beneficial for these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!